Personalized Cancer Care. Realized.
Forging a Clearer Path to Cancer Treatments
Exercise of TO 3 warrants: Read Exercise period: August 30 – September 13
Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on the NASDAQ First North, Allarity (ALLR: SS) is headquartered in Horsholm, Denmark, with US operations, and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Extraordinary General Meeting
Time: 1:00p.m. CEST